Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2021-08-25 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
标签
MSS/ MMRp
|
| NCT ID NCT04591431 |
TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | 阶段
第二阶段
|
Date Added 2020-10-19 |
地点
意大利
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib |
标签
MSS/ MMRp
|
| NCT ID NCT03985891 |
TitleJS001 联合化疗对局部晚期结肠癌患者的疗效 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2019-06-14 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04984369 |
TitleHLX208（BRAF V600E 抑制剂）联合西妥昔单抗治疗一线治疗后出现 BRAF V600E 突变的转移性结直肠癌 (mCRC) 的疗效观察 | 阶段
第二阶段
|
Date Added 2021-07-30 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Cetuximab Injection [Erbitux], HLX208 |
标签
MSS/ MMRp
|
| NCT ID NCT02925234 |
Title药物再发现方案（DRUP 试验） | 阶段
第二阶段
|
Date Added 2016-10-05 |
地点
荷兰
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04535024 |
TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | 阶段
第二阶段
|
Date Added 2020-09-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Sintilimab |
标签
MSS/ MMRp
|
| NCT ID NCT04948034 |
Title转移性结直肠癌中的福格替尼、替利珠单抗和立体定向消融放疗联合疗法（RIFLE） | 阶段
第二阶段
|
Date Added 2021-07-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Fruquintinib, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02298959 |
TitleTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | 阶段
第 1 阶段
|
Date Added 2014-11-24 |
地点
Florida, United States
Maryland, United States Massachusetts, United States 加拿大 |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap |
标签
MSS/ MMRp
|
| NCT ID NCT03502733 |
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | 阶段
第 1 阶段
|
Date Added 2018-04-19 |
地点
Maryland, United States
Texas, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo |
标签
MSS/ MMRp
|
| NCT ID NCT05673148 |
TitleERASur研究：测试在有限转移性结直肠癌的常规系统疗法基础上增加全烧蚀疗法的效果 | 阶段
第三阶段
|
Date Added 2023-01-06 |
地点
Arizona, United States
California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States |
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
化疗 |
标签
MSS/ MMRp
|
